This is a profitable, passive epilepsy management app founded in 2023. Since launch, the business has grown to nearly $105K in trailing 12-month revenue with a 93% profit margin, all while requiring just 1 hour per week of founder time over the past year. MRR has grown from $7,300 to $8,700 over the last 12 months, reflecting steady, compounding recurring revenue. Recognized by a leading national epilepsy advocacy organization as a top epilepsy technology platform, the app combines phone and smartwatch seizure detection that connects patients and caregivers in real time. The business runs lean, with zero employees, no debt, and monthly operating costs under $600, yet revenue has grown 60% year over year with zero dollars spent on marketing.

Growth to date has been entirely organic, driven by app store search visibility and advocacy organization recognition, proving strong product market fit ahead of any real investment in acquisition. A 35% trial-to-paid conversion rate and a 442-subscriber base generate consistent recurring revenue, while an untapped email list of roughly 19,000 epilepsy patients represents an immediate, low-cost growth lever.

Beyond consumer subscriptions, the business has validated a B2B licensing opportunity, evidenced by a pilot with a major publicly traded pharmaceutical company and an already scoped tiered licensing structure for pharma partners. With under 0.1% penetration of the 3.4-million-person US epilepsy market, and meaningful retention work, paid acquisition, and email activation still unexplored, this business offers a rare combination of proven unit economics, defensible market positioning, and substantial untapped upside for a buyer ready to invest founder attention and growth expertise.  


Key Benefits:

Award-Winning App Recognition: The app is ranked #1 in its category by a leading national health advocacy organization, a distinction that competitors have not achieved.

Exceptional Profit Margins: There is currently a 93% profit margin, with virtually no operating expenses to maintain.

Strong Organic Growth: Consumer subscription revenue grew 30% YoY with zero marketing spend, while total revenue grew 60%, including their first B2B licensing deal.

Proprietary Technology: The proprietary health detection algorithm is protected by trade secrets and prior art.

High Organic Install Volume: Nearly 900 organic app installs per month occur across the App Store and Google Play combined.

Strong Conversion Rate: There is a strong 35% trial-to-paid conversion rate under a hard seven-day paywall model.

Untapped Email List: An unmonetized email list of roughly 19,000 epilepsy patients is ready for activation.

Scalable Licensing Structure: A tiered B2B licensing structure is already scoped and ready to scale with pharma partners.